- ►diabetesjournals.org M Alvarsson, G Sundkvist, I Lager, M … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—ß-Cell function, glycemic control, and quality of
life were monitored over 2 years in 39 patients with islet cell
antibody-negative type 2 diabetes diagnosed 0–2 years before inclusion in ... Cited by 90 - Related articles - BL Direct - All 8 versions
EA Ryan, S Imes, C Wallace - Diabetes care, 2004 - Am Diabetes Assoc OBJECTIVE—Type 2 diabetes is associated with defects in insulin secretion and
insulin action. Hyperglycemia may aggravate these defects, a feature known as
glucose toxicity. Previous studies have shown that acute correction of ... Cited by 136 - Related articles - BL Direct - All 9 versions
- ►endojournals.org K Maedler, RD Carr, D Bosco, RA Zuellig, T … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Loss of ß-cell mass and function raises a concern regarding the application of
sulfonylureas for the treatment of type 2 diabetes because previous studies have
shown that agents that cause closure of inwardly rectifying K + ... Cited by 79 - Related articles - All 6 versions
Y Li, W Xu, Z Liao, B Yao, X Chen, Z Huang, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Optimal glycemic control was achieved within 6.3 ± 3.9 days by CSII
in 126 patients. The remission rates (percentages maintaining near euglycemia)
at the third, sixth, twelfth, and twenty-fourth month were 72.6, 67.0, ... Cited by 120 - Related articles - BL Direct - All 8 versions
S Del Guerra, L Marselli, R Lupi, U Boggi, F … - Journal of diabetes and its complications, 2005 - Elsevier The direct effects of prolonged exposure to sulphonylureas on the function and
survival of human islets are unknown. This study assessed the insulin content,
glucose-stimulated insulin release, islet cell apoptosis, and mRNA ... Cited by 23 - Related articles - All 10 versions
H Ilkova, B Glaser, A Tunckale, N Bagriacik, E … - Diabetes Care, 1997 - Am Diabetes Assoc OBJECTIVE: Type 2 diabetes is a slowly progressive disease, in which the gradual
deterioration of glucose tolerance is associated with the progressive decrease
in beta-cell function. Hyperglycemia per se has deleterious effects on both ... Cited by 264 - Related articles - BL Direct - All 6 versions
E Björk, C Berne, O Kämpe, L Wibell, P … - Diabetes, 1996 - Am Diabetes Assoc Twenty islet cell antibody (ICA)-positive patients, aged 19-38 years, with IDDM
were randomized at onset to treatment with either diazoxide, a K+ channel opener
that inhibits the release of insulin, or placebo for 3 months, in addition ... Cited by 84 - Related articles - BL Direct - All 5 versions
WJ Andrews, B Vasquez, M Nagulesparan, I … - Diabetes, 1984 - Am Diabetes Assoc The effects of rigorous insulin treatment on insulin action (insulin clamp) and
secretion (plasma insulin response to glucose) were studied in 13 obese patients
with non-insulin-dependent diabetes mellitus (NIDDM). Improvements were ... Cited by 122 - Related articles - All 4 versions
L Karvestedt, G Andersson, S Efendic, V Grill - Journal of internal medicine, 2002 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 16 - Related articles - BL Direct - All 5 versions
B Glaser, G Leibovich, R Nesher, S Hartling, … - Acta Endocrinologica, 1988 - eje.org Abstract. In Type II, non-insulin-dependent diabetes, insulin secretion is often
reduced to the point where oral hypoglycaemic agents fail to control the plasma
glucose level. We studied 12 patients (age 41–66 years; 4 lean, 8 obese) ... Cited by 62 - Related articles - All 8 versions
